#ROIVW

StockTitan

@stocktitan.net

1 week ago

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna Roivant (Nasdaq: ROIV) announced Genevant and Arbutus reached a $2.25 billion global settlement with Moderna on March 3, 2026. Moderna will pay $950 million upfront in July 2026 and up to $1.3 billion contingent on a favorable Section 1498 appellate outcome.The settlement includes entry of judgment of infringement and no invalidity for four patents, a global non-exclusive LNP license to Moderna for infectious-disease SM-102 mRNA vaccines, and ends related litigation with Moderna. Roivant approved a $1 billion share repurchase program.

#ROIV #ROIVW Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

www.stocktitan.net/news/ROIV/roivant-announ...

StockTitan

@stocktitan.net

1 week ago

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis Priovant Therapeutics (NASDAQ:ROIV) announced FDA acceptance of its NDA for brepocitinib in dermatomyositis with Priority Review and a PDUFA target action date in Q3 2026. The company expects a U.S. launch at the end of September 2026 if approved.Priority Review was supported by positive Phase 3 VALOR results (N=241), described as the first positive 52-week placebo-controlled trial in dermatomyositis; approval would represent the first targeted therapy for the disease.

#ROIV #ROIVW Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

www.stocktitan.net/news/ROIV/priovant-annou...

StockTitan

@stocktitan.net

3 months ago

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day Roivant (Nasdaq: ROIV) outlined accelerated late‑stage timelines and commercialization plans at its 2025 Investor Day, forecasting 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof‑of‑concept readouts over the next three years.Key updates: brepocitinib NDA for dermatomyositis expected in early 2026 with launch planned early 2027; brepocitinib topline data for non‑infectious uveitis now expected H2 2026; cutaneous sarcoidosis PoC topline H1 2026; IMVT‑1402 D2T RA topline data expected in 2026. Roivant‑led Immunovant financing raised ~$550 million, extending Immunovant cash runway to IMVT‑1402 launch. Ongoing litigation schedules include a US Moderna jury trial in March 2026.

#ROIV #ROIVW Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

www.stocktitan.net/news/ROIV/roivant-highli...

StockTitan

@stocktitan.net

4 months ago

#ROIV #ROIVW Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

www.stocktitan.net/news/ROIV/roivant-report...

StockTitan

@stocktitan.net

6 months ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients Immunovant (Nasdaq: IMVT) has revealed promising six-month remission data for batoclimab in treating uncontrolled Graves' disease. In a proof-of-concept study, approximately 80% (17/21) of patients maintained normal thyroid function six months after treatment cessation, with 50% (8/17) of responders achieving anti-thyroid drug (ATD) free remission.The study involved a 24-week treatment period with batoclimab administered subcutaneously, followed by a 24-week off-treatment follow-up. The treatment demonstrated strong durability, with an additional 30% (5/17) of responding patients requiring only minimal ATD doses. Safety and tolerability were consistent with previous batoclimab studies.Two potentially registrational trials for IMVT-1402, the company's lead compound, are currently enrolling patients, with topline results expected in 2027.

#ROIV #ROIVW Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

www.stocktitan.net/news/ROIV/roivant-unveil...

StockTitan

@stocktitan.net

7 months ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update Roivant Sciences (Nasdaq: ROIV) reported Q1 2025 financial results and business updates. The company maintained a strong financial position with $4.5 billion in consolidated cash and marketable securities as of June 30, 2025. Key highlights include completion of a $1.5 billion share repurchase program, reducing outstanding shares by over 15%, and board approval for an additional $500 million buyback program.Financial results showed R&D expenses increased to $152.9 million from $120.5 million year-over-year, while G&A expenses rose to $134.0 million. The company reported a net loss from continuing operations of $273.9 million ($0.33 per share).Clinical progress remains on track with multiple milestone readouts expected, including brepocitinib's Phase 3 VALOR study in dermatomyositis in H2 2025 and IMVT-1402's advancement in six indications.

#ROIV #ROIVW Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

www.stocktitan.net/news/ROIV/roivant-report...

StockTitan

@stocktitan.net

9 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update Roivant (NASDAQ: ROIV) reported financial results for Q4 and fiscal year ended March 31, 2025. The company maintains a strong financial position with $4.9B in consolidated cash and marketable securities. Key highlights include: $1.3B share repurchase program reducing outstanding shares by 14%, continued progress in brepocitinib trials with expected readouts in 2026-2027, and expansion of IMVT-1402 development into six indications. Financial results show R&D expenses increased to $145.2M in Q4 2025 from $107.6M in Q4 2024, while G&A expenses rose to $147.1M from $108.1M. The company reported a loss from continuing operations of $252.4M for Q4 2025. Notable developments include leadership changes at Immunovant and expansion of LNP litigation against Moderna to international markets.

#ROIV #ROIVW Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

www.stocktitan.net/news/ROIV/roivant-report...

StockTitan

@stocktitan.net

11 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from

#ROIV #ROIVW Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

www.stocktitan.net/news/ROIV/roivant-announ...

StockTitan

@stocktitan.net

1 year ago

Roivant's $5.2B War Chest Fuels Ambitious Clinical Pipeline as Loss Widens in Q3 Roivant reports $5.2B cash position and expands brepocitinib development, while posting $208.9M loss. Key milestones ahead with IMVT-1402 trials and batoclimab results.

#ROIV #ROIVW Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

www.stocktitan.net/news/ROIV/roivant-report...

StockTitan

@stocktitan.net

1 year ago

Virtual Dermatology Startup Zest Health Secures $13M to Combat $40B Biologics Crisis Digital health platform Zest Health secures $13M seed funding to revolutionize dermatology care, showing 80% patient improvement rates and targeting $40B+ in excessive biologics spending.

#ROIV #ROIVW Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

www.stocktitan.net/news/ROIV/zest-health-an...

StockTitan

@stocktitan.net

1 year ago

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis | ROIV Stock News  Kinevant Sciences, a clinical-stage

#ROIV #ROIVW Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

#StockMarket #stocks #investing

www.stocktitan.net/news/ROIV/kinevant-scien...

StockTitan

@stocktitan.net

1 year ago

Roivant Sciences' Namilumab Fails Phase 2 Sarcoidosis Trial, Development Halted | ROIV Stock News Roivant's namilumab drug misses primary and secondary endpoints in Phase 2 RESOLVE-Lung study for pulmonary sarcoidosis, leading to discontinuation of development program.

#ROIV #ROIVW Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

#StockMarket #news #investing

www.stocktitan.net/news/ROIV/roivant-announ...